DMPI DelMar Pharmaceuticals Inc.

0.6
-0.01  -2%
Previous Close 0.62
Open 0.62
Price To Book -2.33
Market Cap 6,884,338
Shares 11,388,483
Volume 63,400
Short Ratio
Av. Daily Volume 966,791

NewsSee all news

  1. DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  2. DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

    SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  3. DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  4. DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

    SAN DIEGO, Sept. 4, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  5. DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

    VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment to be completed 4Q 2020. Potential update due at the Society of Neuro-Oncology meeting November 20-24, 2019.
VAL-083
MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)
Phase 2 enrolment to be completed 4Q 2020. Potential update due at the Society of Neuro-Oncology meeting November 20-24, 2019.
VAL-083
MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Latest News

  1. DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  2. DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

    SAN DIEGO, Sept. 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced

  3. DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  4. DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

    SAN DIEGO, Sept. 4, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today

  5. DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

    VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the

  6. Thinking about buying stock in Aurora Cannabis, American Express, Walt Disney Co, DelMar Pharmaceuticals, or Tilray?

    NEW YORK, Aug. 26, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AXP, DIS, DMPI, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the